Developer docs
API playgroundTry for free, no card

Search company profiles

2Flo Ventures

Full company profile

uuid0005quv

Namestring
2Flo Ventures
Legal namestring
2Flo Ventures
Company typeenum
Private
Founded yearint
2021
Descriptiontext

2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio founded in 2021 that invests in healthcare and life sciences companies addressing large unmet medical needs and health disparities. The firm operates a dual model, deploying equity capital into portfolio companies while also providing hands-on operational support across regulatory, clinical, commercial, and financial domains through a 40+ advisor network and a five-person core team led by Managing Partner Paul Burton, JD, MBA. Its portfolio of nine companies spans biotechnology (Vivacelle Bio's phospholipid nanoparticle VBI-S for septic shock, Temprian Therapeutics' HSP70i immunotherapy for autoimmune disease, Akan Biosciences' StroMel SVF stem cell therapy), medical devices, and digital health (CancerIQ's EHR-integrated precision health platform used at 180+ locations, 4D Healthware's enhanced telehealth platform, KeyCare built natively inside Epic). Portfolio companies have collectively raised over $85 million across rounds including a $14M CancerIQ Series B co-led by Merck GHI and Amgen Ventures, a $5.3M US Navy award to Vivacelle Bio, and prior backing from HealthX Ventures, McKesson Ventures, and OSF Ventures.

The firm's business model combines traditional VC economics—management fees on managed capital and carried interest on exits—with startup studio economics in which operational support is exchanged for equity at company inception. Deal sourcing runs through a 'Pitch to Us' Airtable form, warm introductions via the advisor network, and a recurring event ecosystem including the annual Health Equity Investing Symposium (2023-2025, with 2026 announced), the Health Equity Pitch Competition (launched 2025), the Martha's Vineyard Summit, and the SF JPM Reception co-hosted with Women of Color in Pharma. Strategic brand-building activity includes an op-ed in Fierce Healthcare, conference presence at BIO International Convention and JP Morgan Healthcare Conference, and recognition including Temprian Therapeutics as a Nature Spinoff Prize 2020 finalist and the in-house Health Equity Titan of the Year Award presented to Dr. Aletha Maybank at the 2025 Women's Health Edition Symposium. Customers, in the LP and founder sense, are institutional and strategic investors, early-stage healthcare and life sciences entrepreneurs, and health systems adopting portfolio technologies.

Short descriptiontext

2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and builds healthcare and life sciences companies advancing health equity, supported by a 40+ advisor network and nine portfolio companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, startup studio services, health equity investing, life sciences funding, early-stage investment
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Venture Capital Fund Management
TypeSubscription Recurring
Description

2Flo Ventures generates returns through traditional VC mechanisms: management fees on managed funds, carried interest (performance fees) on successful portfolio company exits, and co-investment rights. The firm builds and invests in early-stage healthcare companies with the goal of generating meaningful returns for stakeholders while advancing health equity.

2floventures.com
2Startup Studio Services
TypeProfessional Services
Description

As a startup studio, 2Flo Ventures provides operational support, strategic guidance, regulatory expertise, commercial strategy, and network access to portfolio companies. In return, the firm builds equity stakes in portfolio companies. The studio model allows 2Flo to shape companies from inception and capture greater value at exit.

2floventures.com
3Portfolio Company Capital Raising
TypeLicensing Royalties
Description

2Flo Ventures portfolio companies raise independent funding rounds from institutional investors and strategic partners. Examples: CancerIQ raised $4.8M Series A (led by HealthX Ventures) and $14M Series B (co-led by Merck GHI and Amgen Ventures). Vivacelle Bio received a $5.3M award from the US Navy. These rounds generate dilution for 2Flo but increase portfolio valuation.

2floventures.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Marketing or Sales, Operations
Pricing details2 tiers
1Venture Investment — negotiated per company
ModelOtherBilling cadenceMulti-year contract
Notes

2Flo Ventures invests equity capital in early-stage healthcare companies. Investment amounts and ownership stakes are not publicly disclosed. The firm operates as both an investor and startup studio, providing capital alongside operational support.

2floventures.com
2Health Equity Pitch Competition — prize structure
ModelOutcome Based/ PerformanceBilling cadenceAnnual
Notes

1st Place: $1,000 cash + $5,000 in-kind donations; 2nd Place: $600 cash + $2,000 in-kind; 3rd Place: $400 + $1,000 in-kind. In-kind support from leaders across Chicago ecosystem including legal, finance, pitch coaching, strategy, marketing, regulatory, business development, and design.

2floventures.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and helps build healthcare and life sciences companies addressing large unmet medical needs and advancing health equity. The firm deploys equity capital into nine portfolio companies spanning biotechnology, medical devices, and digital health, while providing hands-on operational support, regulatory expertise, commercial strategy, and access to a 40+ advisor network. It also operates a proprietary event ecosystem (annual Health Equity Investing Symposium, Health Equity Pitch Competition, Martha's Vineyard Summit, and SF JPM Reception) to source deals and cultivate a community of founders and investors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Portfolio companies have collectively raised over $85 million and employ over 100 people across 9 companies
+3 more records
Product and service4 records
1Venture Capital Investment
CategoryVenture Capital / Equity Investment
Description

Early-stage equity capital investment in healthcare and life sciences startups addressing large unmet medical needs and advancing health equity. Investment amounts and ownership stakes are negotiated per company; supported by an inbound 'Pitch to Us' Airtable funnel, warm advisor introductions, and event-driven deal sourcing. Portfolio includes Vivacelle Bio, Temprian Therapeutics, Delphian Therapeutics, ResQ Pharma, KeyCare, CancerIQ, Temprian Oncology, Akan Biosciences, and 4D Healthware.

2Startup Studio Services
CategoryStartup Studio / Operational Support
Description

Hands-on operational support provided to portfolio companies from inception, including regulatory expertise, commercial strategy, financial guidance, and access to a 40+ advisor network spanning venture partners, senior advisors, strategic advisors, regulatory advisors, commercial advisors, healthcare advisors, and finance advisors. In return, the studio builds equity stakes and shapes companies from inception.

3Health Equity Pitch Competition
CategoryAnnual Event / Competition
Description

Annual pitch competition for idea-stage and early-stage founders with novel solutions advancing health equity; industry-agnostic with focus on the specific health equity idea. Awards cash prizes and in-kind donations from Chicago ecosystem leaders across legal, finance, pitch coaching, strategy, marketing, regulatory, business development, and design domains (1st: $1,000 cash + $5,000 in-kind; 2nd: $600 cash + $2,000 in-kind; 3rd: $400 + $1,000 in-kind). Applications via Google Forms; finalists present in person in Chicago.

4Health Equity Investing Symposium
CategoryAnnual Event / Symposium
Description

Flagship annual one-day forum bringing together investors, founders, healthcare leaders, and policymakers; features panel discussions, company showcases, Venture Engine presentations, and the Health Equity Titan of the Year award. Sourced and curated by 2Flo Ventures, with themed editions such as the 2025 Women's Health Edition. Functions as a deal-sourcing and community-building event.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-09-18
Description

Rubix LS sponsored the 2025 Health Equity Investing Symposium: Women's Health Edition, with Remarks delivered by Reginald Swift of Rubix LS.

Strategic tierMinorTypeOthersAnnounced on2025-04-11
Description

Cushman & Wakefield generously provides event space in Chicago to host 2Flo Ventures' Health Equity Pitch Competition events. This enables the firm to hold its annual pitch competition in person at a Chicago venue, supporting the firm's community-building and deal-sourcing mission.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-15
Description

2Flo Ventures partnered with Sepsis Alliance for the 2024 Health Equity Investing Symposium. Sepsis Alliance leads efforts to save lives and reduce suffering from infections and sepsis through public education, healthcare professional training, regulatory advocacy, and research collaboration. All proceeds from the 2024 symposium were donated to Sepsis Alliance.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-08-15
Description

Latham & Watkins served as a sponsor of the 2024 Health Equity Investing Symposium. Sponsorship supports the event's community-building and thought leadership objectives.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-08-15
Description

Cooley served as a sponsor of the 2024 Health Equity Investing Symposium and co-hosted the SF JPM Reception with 2Flo Ventures and WOCIP.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-08-15
Description

ISTC, through its Venture Engine program, co-sponsored the 2024 Health Equity Investing Symposium and hosted the Venture Engine Showcase featuring early-stage life science and biotech companies.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-08-15
Description

CBRE served as a sponsor of the 2024 Health Equity Investing Symposium.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-08-15
Description

Loop Capital served as a sponsor of the 2024 Health Equity Investing Symposium.

9Michael Best
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-08-15
Description

Michael Best served as a sponsor of the 2024 Health Equity Investing Symposium.

2floventures.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-12
Description

2Flo Ventures co-hosts the annual SF JPM Reception with Women of Color in Pharma (WOCIP) during JP Morgan Healthcare Conference week in San Francisco. The event brings together healthcare leaders, investors, and innovators for networking and discussion. 2Flo Managing Partner Charlotte Jones-Burton founded and presides over WOCIP, creating a strong co-founding relationship.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

World Business Chicago, in partnership with Mayor Brandon Johnson, announced the Chicago Venture Summit: Future of Health for October 2026. 2Flo Ventures operates within Chicago's healthcare innovation ecosystem and participates in regional economic development initiatives promoting Chicagoland's healthcare sector.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biotech-focused venture firm that builds and launches healthcare companies from inception. Direct peer in the startup-studio / company-creation model for life sciences, although operating at much larger scale and exclusively in therapeutics.

TypeDirect peer
Description

Wisconsin-based digital health-focused early-stage VC. Direct peer — HealthX led CancerIQ's Series A and participated in its Series B alongside 2Flo, and shares a digital-health/health-equity investment thesis targeting the Midwest healthcare ecosystem.

TypeBroad incumbent
Description

Large, established venture firm focused on early-stage life sciences and physical sciences companies. Broad incumbent with overlapping sector exposure (biotech/therapeutics) but materially larger fund sizes and broader portfolio than 2Flo's boutique health-equity studio.

TypeDirect peer
Description

Boston-based early-stage healthcare technology VC investing across digital health, health IT, and care delivery. Direct peer in the early-stage, healthcare-focused VC category with similar check sizes and similar thesis on transforming care delivery.

TypeEmerging player
Description

Impact-focused venture firm investing in early-stage companies addressing gaps for underrepresented communities, with a notable health-equity lens. Emerging player with overlapping health-equity impact thesis and similar commitment to underrepresented founders.

TypeBroad incumbent
Description

Flagship is a bioplatform innovation company that conceives, creates, and grows biotech companies from internal hypotheses — the gold-standard biotech startup studio. Broad incumbent analogue for 2Flo's studio model, though operating at vastly larger scale.

TypeDirect peer
Description

Early-stage health tech and digital health VC with a thesis aligned with democratizing healthcare access. Direct peer in mission-aligned, early-stage healthcare venture investing.

TypeEmerging player
Description

Digital health venture fund and advisory platform supporting early-stage companies and convening the digital health ecosystem. Emerging player with overlapping digital-health focus and similar community/event-driven approach to deal sourcing.

TypeDirect peer
Description

Early-stage venture firm with a healthcare and technology focus, often writing first checks alongside operators. Direct peer given similar stage, sector breadth, and willingness to syndicate with strategic healthcare investors.

TypeBroad incumbent
Description

Large venture franchise with a dedicated Bio + Health fund investing across digital health, biotech, and care delivery. Broad incumbent that competes for the same healthcare founder pool at significantly larger check sizes.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks2 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

2Flo Ventures

Healthcare Venture Capital2floventures.com

2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and builds healthcare and life sciences companies advancing health equity, supported by a 40+ advisor network and nine portfolio companies.

What 2Flo Ventures does

2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio founded in 2021 that invests in healthcare and life sciences companies addressing large unmet medical needs and health disparities. The firm operates a dual model, deploying equity capital into portfolio companies while also providing hands-on operational support across regulatory, clinical, commercial, and financial domains through a 40+ advisor network and a five-person core team led by Managing Partner Paul Burton, JD, MBA. Its portfolio of nine companies spans biotechnology (Vivacelle Bio's phospholipid nanoparticle VBI-S for septic shock, Temprian Therapeutics' HSP70i immunotherapy for autoimmune disease, Akan Biosciences' StroMel SVF stem cell therapy), medical devices, and digital health (CancerIQ's EHR-integrated precision health platform used at 180+ locations, 4D Healthware's enhanced telehealth platform, KeyCare built natively inside Epic). Portfolio companies have collectively raised over $85 million across rounds including a $14M CancerIQ Series B co-led by Merck GHI and Amgen Ventures, a $5.3M US Navy award to Vivacelle Bio, and prior backing from HealthX Ventures, McKesson Ventures, and OSF Ventures.

The firm's business model combines traditional VC economics—management fees on managed capital and carried interest on exits—with startup studio economics in which operational support is exchanged for equity at company inception. Deal sourcing runs through a 'Pitch to Us' Airtable form, warm introductions via the advisor network, and a recurring event ecosystem including the annual Health Equity Investing Symposium (2023-2025, with 2026 announced), the Health Equity Pitch Competition (launched 2025), the Martha's Vineyard Summit, and the SF JPM Reception co-hosted with Women of Color in Pharma. Strategic brand-building activity includes an op-ed in Fierce Healthcare, conference presence at BIO International Convention and JP Morgan Healthcare Conference, and recognition including Temprian Therapeutics as a Nature Spinoff Prize 2020 finalist and the in-house Health Equity Titan of the Year Award presented to Dr. Aletha Maybank at the 2025 Women's Health Edition Symposium. Customers, in the LP and founder sense, are institutional and strategic investors, early-stage healthcare and life sciences entrepreneurs, and health systems adopting portfolio technologies.

2Flo Ventures firmographics

Firmographics
Name
2Flo Ventures
Legal name
2Flo Ventures
Website
https://2floventures.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and builds healthcare and life sciences companies advancing health equity, supported by a 40+ advisor network and nine portfolio companies.
Ownership category
akta.pro rank

2Flo Ventures industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Healthcare venture capital
  • Startup studio services
  • Health equity investing
  • Life sciences funding
  • Early-stage investment

Where 2Flo Ventures is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

2Flo Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Marketing or Sales, Operations

Revenue model

  1. Venture Capital Fund Management: 2Flo Ventures generates returns through traditional VC mechanisms: management fees on managed funds, carried interest (performance fees) on successful portfolio company exits, and co-investment rights. The firm builds and invests in early-stage healthcare companies with the goal of generating meaningful returns for stakeholders while advancing health equity.
  2. Startup Studio Services: As a startup studio, 2Flo Ventures provides operational support, strategic guidance, regulatory expertise, commercial strategy, and network access to portfolio companies. In return, the firm builds equity stakes in portfolio companies. The studio model allows 2Flo to shape companies from inception and capture greater value at exit.
  3. Portfolio Company Capital Raising: 2Flo Ventures portfolio companies raise independent funding rounds from institutional investors and strategic partners. Examples: CancerIQ raised $4.8M Series A (led by HealthX Ventures) and $14M Series B (co-led by Merck GHI and Amgen Ventures). Vivacelle Bio received a $5.3M award from the US Navy. These rounds generate dilution for 2Flo but increase portfolio valuation.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractVenture Investment — negotiated per company
Outcome Based/ PerformanceAnnualHealth Equity Pitch Competition — prize structure

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

2Flo Ventures product offering

Product offering

Core offering

2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and helps build healthcare and life sciences companies addressing large unmet medical needs and advancing health equity. The firm deploys equity capital into nine portfolio companies spanning biotechnology, medical devices, and digital health, while providing hands-on operational support, regulatory expertise, commercial strategy, and access to a 40+ advisor network. It also operates a proprietary event ecosystem (annual Health Equity Investing Symposium, Health Equity Pitch Competition, Martha's Vineyard Summit, and SF JPM Reception) to source deals and cultivate a community of founders and investors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Venture Capital Investment Early-stage equity capital investment in healthcare and life sciences startups addressing large unmet medical needs and advancing health equity. Investment amounts and ownership stakes are negotiated per company; supported by an inbound 'Pitch to Us' Airtable funnel, warm advisor introductions, and event-driven deal sourcing. Portfolio includes Vivacelle Bio, Temprian Therapeutics, Delphian Therapeutics, ResQ Pharma, KeyCare, CancerIQ, Temprian Oncology, Akan Biosciences, and 4D Healthware.
  • Startup Studio Services Hands-on operational support provided to portfolio companies from inception, including regulatory expertise, commercial strategy, financial guidance, and access to a 40+ advisor network spanning venture partners, senior advisors, strategic advisors, regulatory advisors, commercial advisors, healthcare advisors, and finance advisors. In return, the studio builds equity stakes and shapes companies from inception.
  • Health Equity Pitch Competition Annual pitch competition for idea-stage and early-stage founders with novel solutions advancing health equity; industry-agnostic with focus on the specific health equity idea. Awards cash prizes and in-kind donations from Chicago ecosystem leaders across legal, finance, pitch coaching, strategy, marketing, regulatory, business development, and design domains (1st: $1,000 cash + $5,000 in-kind; 2nd: $600 cash + $2,000 in-kind; 3rd: $400 + $1,000 in-kind). Applications via Google Forms; finalists present in person in Chicago.
  • Health Equity Investing Symposium Flagship annual one-day forum bringing together investors, founders, healthcare leaders, and policymakers; features panel discussions, company showcases, Venture Engine presentations, and the Health Equity Titan of the Year award. Sourced and curated by 2Flo Ventures, with themed editions such as the 2025 Women's Health Edition. Functions as a deal-sourcing and community-building event.

Quantifiable outcome

  • Portfolio companies have collectively raised over $85 million and employ over 100 people across 9 companies
  • +3 more outcomes

Companies that use 2Flo Ventures

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

2Flo Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability2 records

Feature5 records

2Flo Ventures partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered minor and core.

  • Rubix LSminorGTM or Marketing Partner · 18 September 2025Rubix LS sponsored the 2025 Health Equity Investing Symposium: Women's Health Edition, with Remarks delivered by Reginald Swift of Rubix LS.
  • Cushman & WakefieldminorOthers · 11 April 2025Cushman & Wakefield generously provides event space in Chicago to host 2Flo Ventures' Health Equity Pitch Competition events. This enables the firm to hold its annual pitch competition in person at a Chicago venue, supporting the firm's community-building and deal-sourcing mission.
  • Sepsis AlliancecoreStrategic or Co-development Partner · 15 August 20242Flo Ventures partnered with Sepsis Alliance for the 2024 Health Equity Investing Symposium. Sepsis Alliance leads efforts to save lives and reduce suffering from infections and sepsis through public education, healthcare professional training, regulatory advocacy, and research collaboration. All proceeds from the 2024 symposium were donated to Sepsis Alliance.
  • Latham & WatkinsminorGTM or Marketing Partner · 15 August 2024Latham & Watkins served as a sponsor of the 2024 Health Equity Investing Symposium. Sponsorship supports the event's community-building and thought leadership objectives.
  • CooleyminorGTM or Marketing Partner · 15 August 2024Cooley served as a sponsor of the 2024 Health Equity Investing Symposium and co-hosted the SF JPM Reception with 2Flo Ventures and WOCIP.
  • Illinois Science and Technology Coalition (ISTC)minorGTM or Marketing Partner · 15 August 2024ISTC, through its Venture Engine program, co-sponsored the 2024 Health Equity Investing Symposium and hosted the Venture Engine Showcase featuring early-stage life science and biotech companies.
  • CBREminorGTM or Marketing Partner · 15 August 2024CBRE served as a sponsor of the 2024 Health Equity Investing Symposium.
  • Loop CapitalminorGTM or Marketing Partner · 15 August 2024Loop Capital served as a sponsor of the 2024 Health Equity Investing Symposium.
  • Michael BestminorGTM or Marketing Partner · 15 August 2024Michael Best served as a sponsor of the 2024 Health Equity Investing Symposium.
  • Women of Color in Pharma (WOCIP)coreStrategic or Co-development Partner · 12 January 20242Flo Ventures co-hosts the annual SF JPM Reception with Women of Color in Pharma (WOCIP) during JP Morgan Healthcare Conference week in San Francisco. The event brings together healthcare leaders, investors, and innovators for networking and discussion. 2Flo Managing Partner Charlotte Jones-Burton founded and presides over WOCIP, creating a strong co-founding relationship.
  • World Business ChicagominorStrategic or Co-development PartnerWorld Business Chicago, in partnership with Mayor Brandon Johnson, announced the Chicago Venture Summit: Future of Health for October 2026. 2Flo Ventures operates within Chicago's healthcare innovation ecosystem and participates in regional economic development initiatives promoting Chicagoland's healthcare sector.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

2Flo Ventures competitors and assessment

Company assessment

Direct peers

  • Third Rock Ventures: Biotech-focused venture firm that builds and launches healthcare companies from inception. Direct peer in the startup-studio / company-creation model for life sciences, although operating at much larger scale and exclusively in therapeutics.
  • HealthX Ventures: Wisconsin-based digital health-focused early-stage VC. Direct peer — HealthX led CancerIQ's Series A and participated in its Series B alongside 2Flo, and shares a digital-health/health-equity investment thesis targeting the Midwest healthcare ecosystem.
  • Flare Capital Partners: Boston-based early-stage healthcare technology VC investing across digital health, health IT, and care delivery. Direct peer in the early-stage, healthcare-focused VC category with similar check sizes and similar thesis on transforming care delivery.
  • Civilization Ventures: Early-stage health tech and digital health VC with a thesis aligned with democratizing healthcare access. Direct peer in mission-aligned, early-stage healthcare venture investing.
  • Maverick Ventures: Early-stage venture firm with a healthcare and technology focus, often writing first checks alongside operators. Direct peer given similar stage, sector breadth, and willingness to syndicate with strategic healthcare investors.

Broad incumbents

  • ARCH Venture Partners: Large, established venture firm focused on early-stage life sciences and physical sciences companies. Broad incumbent with overlapping sector exposure (biotech/therapeutics) but materially larger fund sizes and broader portfolio than 2Flo's boutique health-equity studio.
  • Flagship Pioneering: Flagship is a bioplatform innovation company that conceives, creates, and grows biotech companies from internal hypotheses — the gold-standard biotech startup studio. Broad incumbent analogue for 2Flo's studio model, though operating at vastly larger scale.
  • Andreessen Horowitz (a16z) Bio + Health Fund: Large venture franchise with a dedicated Bio + Health fund investing across digital health, biotech, and care delivery. Broad incumbent that competes for the same healthcare founder pool at significantly larger check sizes.

Emerging players

  • Kapor Capital: Impact-focused venture firm investing in early-stage companies addressing gaps for underrepresented communities, with a notable health-equity lens. Emerging player with overlapping health-equity impact thesis and similar commitment to underrepresented founders.
  • Rock Health: Digital health venture fund and advisory platform supporting early-stage companies and convening the digital health ecosystem. Emerging player with overlapping digital-health focus and similar community/event-driven approach to deal sourcing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks2 records

Key highlights6 records

Customer concentration

2Flo Ventures social profiles

Digital presence

2Flo Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

2Flo Ventures leadership team

Management profile

Number of profiles

Profiles1 record

2Flo Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

2Flo Ventures M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 2Flo Ventures

What does 2Flo Ventures do?

2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and helps build healthcare and life sciences companies addressing large unmet medical needs and advancing health equity. The firm deploys equity capital into nine portfolio companies spanning biotechnology, medical devices, and digital health, while providing hands-on operational support, regulatory expertise, commercial strategy, and access to a 40+ advisor network. It also operates a proprietary event ecosystem (annual Health Equity Investing Symposium, Health Equity Pitch Competition, Martha's Vineyard Summit, and SF JPM Reception) to source deals and cultivate a community of founders and investors.

Is 2Flo Ventures a public or private company?

2Flo Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was 2Flo Ventures founded?

2Flo Ventures was founded in 2021. It employs 11 to 50 people.

Where is 2Flo Ventures based?

2Flo Ventures is headquartered in Chicago, United States, in the North America region.

How does 2Flo Ventures make money?

Three revenue lines are on record. Venture Capital Fund Management is the primary driver. The others are startup Studio Services and portfolio Company Capital Raising.

Who are 2Flo Ventures's main competitors?

Direct peers on record are Third Rock Ventures, HealthX Ventures, Flare Capital Partners, Civilization Ventures and Maverick Ventures. Broad incumbents are ARCH Venture Partners, Flagship Pioneering and Andreessen Horowitz (a16z) Bio + Health Fund. Emerging players are Kapor Capital and Rock Health.

Does 2Flo Ventures have an API?

No public API is recorded for 2Flo Ventures.

What industry is 2Flo Ventures in?

2Flo Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals